Drug Profile
Research programme: Pneumococcal antibodies - Kyowa Kirin/Valneva
Alternative Names: Pneumococcus antibodies - Kyowa Kirin/Valneva; Streptococcus pneumoniae antibodies - Kyowa Kirin/ValnevaLatest Information Update: 16 Jul 2019
Price :
$50
*
At a glance
- Originator Intercell
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pneumococcal infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pneumococcal-infections in Austria (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pneumococcal-infections in Japan (Parenteral)
- 02 Jul 2013 Pneumococcal antibodies are still in preclinical development for Streptococcus pneumoniae, presumably in Japan and Austria